Ophthalmic Products Presentation

8/9/2019 Ophthalmic Products Presentation

1/19

Ophthalmics

Antiglaucomatic agents

Products presentation

NSAID


2/19

Antiglaucomatic agents

Corneax

(brimonidine)

Ophthalmics

Dorolad (dorzolamide)

Dotiz

(dorzolamide + timolol)

X-iop

(latanoprost)

Tinoprost (latanoprost + timolol)


3/19

Product characteristics

Active in redient:Brimonidine tartrate

Corneax

Pharmaceutical form:Eye drops, solution

Route of administration:Ophthalmic use

Strength:0,2% w/w

Packaging:1 vial x 5 ml


4/19

Therapeutic indications - dosage

Corneax

is indicated for the reduction of elevated intraocular ressure

Corneax

(IOP) in patients with open angle glaucoma or ocular hypertension:

as monotherapy, in patients in whom topical beta-blocker therapy is

contraindicated

as adjunctive therapy to other intraocular pressure lowering

medications, when the target IOP is not achieved with a single agent

Dosage: one drop to each eye(s) twice daily, ~12 hours apart


5/19


Active in redient:Dorzolamide as h drochloride

Dorolad



Strength:2% w/w



6/19


7/19


Active in redients: Dorzolamide as h drochloride + Timolol as

Dotiz

maleate)


Route of administration:Ophthalmic use Strength:2,0%+0,5% w/v



8/19


Dotiz

is indicated for the treatment of elevated intraocular ressure

Dotiz

(IOP) in patients with open-angle glaucoma or pseudoexfoliative

glaucoma when topical beta-blocker monotherapy is not sufficient

Dosage: one drop, twice daily


9/19


Active in redient:Latano rost

X-iop



Strength:0,005% w/v

Packaging:1 vial x 2,5 ml


10/19


X-io

is indicated for the treatment of elevated intraocular ressure

X-iop

(IOP) in patients with open-angle glaucoma or ocular hypertension

Dosage: one drop, once daily. It is recommended to use the product at

night before bedtime


11/19


Active in redient:Latano rost + Timolol as maleate

Tinoprost



Strength:(50 mcg + 5 mg)/ml

Packaging:1 vial x 2,5 ml


12/19


Tino rost

is indicated for the treatment of elevated intraocular

Tinoprost

pressure (IOP) in patients with open-angle glaucoma or ocular

hypertension, where treatment with -blockers or prostaglandin

analogues

Dosage: one drop, once daily


13/19

Ophthalmics

Antimicrobial agent


14/19


Lexacin



Strength:0,5% w/v



15/19


Lexacin

from bacteria (including bacteria conjunctivitis) and microorganisms

susceptible to levofloxacin, in adults and children over 1 year old

Dosage:

1st-2nd day: 1-2 drops in the affected eye(s) every 2 hours, up to 8

times daily

3rd-5th day: 1-2 drops in the affected eye(s), 4 times daily


16/19


Lexacin

prophylaxis and post operative therapy of patients that have undergone

cataract surgery

Dosage:

1 drop, 1 hour before surgery; 1 drop, 30 minutes before surgery

followed by 3 drops at 5-minute intervals just after surgery and

4 drops daily for 6 days staring the day after surgery

Ref: ESCRS Endophthalmitis Study Group, J Cataract Refract Surg 2007


17/19

Ophthalmics

NSAID

Errkes


18/19


Active ingredient:Ketorolac trometamol

Errkes



Strength:0,5% w/v



19/19


Errkes

is indicated for the prevention and treatment of ocular

Errkes

inflammation after cataract surgery

Dosage: one drop, three times daily, starting 24 hours before

surgery and after surgery for 3-4 weeks

Errkes

is also indicated for the temporary relief of ocular itching due to

seasonal allergic conjunctivitis

Dosage: one drop, four times daily to the affected eye(s)

Ophthalmic Products Presentation

Documents

Transcript of Ophthalmic Products Presentation